Skip to Content
NCI Patient-Derived Models Repository (PDMR) - An NCI Precision Oncology Initiative Resource
Contact PDMR
Show menu
Search this site
Last Updated: 05/17/19

ANNOUNCEMENT: All distribution lot PDX, PDOrg, PDC, and CAF material has been tested and proven to be mouse kidney parvovirus (MKPV) negative. We have now incorporated testing of MKPV into our standard murine pathogen screen and this will be present on future updates to our posted Animal Facility Health Reports located on the SOP webpage. For further information about this new atypical strain of mouse parvovirus see the links below. If your center has an animal facility, we strongly recommend that you share the information about MKPV with your veterinarians as MKPV is not detected by the existing parvovirus screens.
Announcement Date: 5/16/2019

Link to recent publication by Roedinger et al.

Link to IDEXX Mouse Opti-XXPress test

Information for Requesting PDX Material

Request Process

  1. Initial distribution will be DOMESTIC ONLY, International distribution will follow. International requestors can request to be placed on a notification list once models can be distributed internationally.
  2. Fill out a PDMR Model Request Form.
  3. Provide no more than a 2-page summary of the research plan for the requested material on the PDMR Model Request Form
  4. If requesting cryopreserved fragments for PDX generation, provide a copy of your ACUC protocol indicating your laboratory or designate uses NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. All NCI Patient Derived Models Repository PDXs must be initially implanted into NSG mice by the recipient for propagation.
  5. If the recipient wishes to expand in other host mouse strains, the recipient should establish a stock of viably cryopreserved fragments from the initial NSG implants and then test PDX take-rates in alternate host strains.
  6. Currently the NCI can only accept payments via checks. No electronic funds transfers can be accepted (see payment procedures in PDMR Material Request Procedures document).
  7. Send the Material Transfer Agreement (MTA) with signatures affixed from both the requestor and authorizing official (required by NCI).
    • Note: For standard requests for research-use of PDMR material, the check-box in bullet #3 does not need to be checked. This is for specific use-case collaborations set-up by the NCI.
  8. Intramural investigators (MD campus) do need to complete the Request Form and Intramural MTA and will go through the same review process as all other Requestors; Intramural investigators can leave the FedEx and Payment Information blank.

Citing NCI Patient-Derived Models and Associated Data

  • To cite the PDMR, use a format similar to that shown below:

    The NCI Patient-Derived Models Repository (PDMR), NCI-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD. URL

  • The full distribution lot name should be used in the publication (e.g., 123456-001-R), not an abbreviated form. In addition, the lot# received and the passage of material used for analysis should be cited.
  • Sequence files downloaded for use in analysis should be referenced including the version# listed in the file name as different pipeline versions may result in different interpretations of the data (e.g., v1.2, v1.3, v2.


  • Material cannot be requested from a specific PDX (sample) in a lineage. Distribution lots are comprised of multiple tumor-bearing mice with the maximum passage for the distribution lot defined in the PDMR database.
  • Viably cryopreserved PDX tumor fragment distribution lots will be provided for those models that (1) are proven to be of human origin, (2) have maintained the histopathology of the host tumor, (3) have at least 95% concordance among the nonsynonymous NCI Cancer Gene Panel variants with an allele frequency > 10% with P0 (NCI defines P0 as the first mouse passage implanted with the original human specimen), (4) are tumorigenic following cryopreservation, (5) are free of a panel of human and rodent pathogens, and (6) have STR sequence homology with the P0 passage. DNA, RNA, and flash-frozen tumor fragments for protein extraction distribution lots will be generated from tumors initiated from the distribution lot.
  • Molecular fractions from PDXs including DNA, RNA, and flash frozen fragments for protein extraction.
    • A viably cryopreserved PDX fragment vial (single vial from a PDX tumor no higher than the listed maximum passage for the distribution lot; sufficient tissue to implant into 2-5 NGS mice)
    • A flash-frozen DNA vial (single vial from a PDX tumor no higher than the listed maximum passage for the distribution lot; approximately 2-3 μg DNA in at least 10 μL prepared using Qiagen's DNA/RNA AllPrep Mini Kit [cat#: 80204])
    • A flash-frozen RNA vial (single vial from a PDX tumor no higher than the listed maximum passage for the distribution lot; approximately 2-3 μg RNA in at least 10 μL prepared using Qiagen's DNA/RNA AllPrep Mini Kit [cat#: 80204]). RNA quality is periodically assessed using an Agilent 2100 Bioanalyzer and vials are maintained if the RIN is >5. For those interested in doing RNASeq, we would recommend requesting a flash-frozen fragment and performing an independent extraction.
    • A flash-frozen PDX fragment vial for protein extraction (single vial with a 30-mg flash-frozen PDX tumor no higher than the listed maximum passage for the distribution lot)